Avian Influenza

Clinical features of avian influenza infection are generally only known in patients requiring hospitalization. Because routine testing for avian influenza is not often necessary unless a patient presents with more severe symptoms, there is little evidence for clinical features or the prevalence of milder infections. Most patients who end up hospitalized present anywhere from 2 to 4 days after exposure but can begin over a week after transmission as well.[9]

Most patients present with symptoms consistent with a flu-like viral illness. In these patients, especially during a known avian influenza outbreak, a thorough history is necessary to evaluate for clues that the illness is due to avian influenza. Additionally, in patients with bird contact and uncharacteristically severe viral symptoms (encephalopathy or organ failure), higher suspicion should be had for AIV infection. Patients that work in the poultry or culinary industries have frequent contact with birds and have greater opportunity to contact the active virus. Most patients with AIV infection have had contact with poultry.[11] Because environment-to-human and human-to-human transmission is theoretically possible with all AIVs and has confirmation in cases of H7N9 infection, even patients with no direct contact with birds can still acquire avian influenza.[12]

Different strains of the avian influenza virus appear to have different characteristic presentations. H5N1, for instance, usually has a presentation that includes fever and lower respiratory tract symptoms and occasionally a prodrome of non-bloody, non-inflammatory diarrhea. Other avian influenza viruses have other characteristic symptoms. H7N9 and other LPAI strains may more commonly be associated with conjunctivitis.[9]

Regardless of characteristic symptoms, if there is a current outbreak, a patient presenting with avian influenza is most likely to have the same strain as other infected patients in the area have.

Diagnosing avian influenza requires high clinical suspicion. In patients who present with viral syndromes and have risk factors such as recent live bird handling or poultry culling, there should be a high suspicion of the disease. Additional testing should evaluate for sequelae of AIV infection, such as respiratory impairment and other organ dysfunction. As the disease can present as a severe respiratory illness, evaluation, and careful monitoring of a patient’s respiratory status should be undertaken for any patient with suspected or confirmed AIV infection. Respiratory intervention may include anywhere from supplemental oxygen to mechanical ventilation to ECMO (extracorporeal membrane oxygenation) in the most severe cases. 

Rapid antigen testing for AIV does exist but is often falsely negative in confirmed cases. The preferred source of a sample for testing is a nasopharyngeal swab or aspirate, but other body fluids are usable if the nasopharyngeal swab or aspirate is not available.[13] Because the infection carries high mortality risk, a negative rapid antigen test should not rule out AIV infection when high suspicion exists. RT-PCR identification of the virus in viral cultures is the standard of care for diagnosis of AIV, and viral detection is typically possible within a few days of disease onset.[9]

Treatment of avian influenza usually consists of supportive care and antiviral medications.[2][9] The majority of care should aim at managing the sequelae of infection. For instance, patients with volume loss or possible electrolyte imbalances should receive volume resuscitation and treatment to correct imbalances. Patients with persistent fever should receive antipyretic medication. Patients with respiratory compromise should be placed on supplemental oxygen and monitored closely for signs of deterioration as these patients are at high risk of requiring intubation and mechanical ventilation.[2][9] As severe disease can cause any range of organ dysfunction and failure, such signs should be closely monitored and aggressively treated to prevent further decompensation.

The World Health Organization released Rapid Advice Guidelines in 2007, outlining consensus treatment recommendations for H5N1 influenza outbreaks.[14] Similar recommendations can likely be used in avian influenza outbreaks due to other strains of the virus. These recommendations include neuraminidase inhibitors (especially oseltamivir) for strongly suspected or confirmed cases of H5N1. The recommendations also suggest avoiding M2 ion channel inhibitors such as amantadine and rimantadine as a single therapy unless neuraminidase inhibitors are not available or the virus is known to be resistant to neuraminidase inhibitors.

The WHO also made recommendations on chemoprophylaxis of those with possible viral exposure in the above guidelines. Of note, oseltamivir (75 mg daily) prophylaxis for 7 to 10 days after last known potential exposure for high-risk groups (household and close family contacts) receives a strong recommendation. Moderate and low-risk groups are not as strongly advised to receive chemoprophylaxis, although moderate risk groups require individual assessment.[14]

Because avian influenza, like many viral illnesses, can present with a variety of symptoms that may be like other disease processes, a broad differential is necessary. For instance, for patients presenting with a headache with or without fever, a differential should include meningitis, intracranial bleeds, migraines, and other headache syndromes. For patients presenting with respiratory symptoms, other infectious upper and lower airway etiologies should be considered, including but not limited to: Bacterial pneumonia, streptococcal pharyngitis, asthma, chronic obstructive pulmonary disease (COPD), pulmonary embolism, and any other diseases affecting the airway. Additionally, in patients with shortness of breath or other possible cardiac involvement, pericarditis and myocarditis should be considered.

Because human cases of avian influenza are relatively rare and generally confined to the individual, unique outbreaks, there has been little opportunity for research on treatment methods for infection, and most recommendations have as their basis on accepted treatment regimens for other types of influenza virus infections. There are, though, some research trials focusing on the efficacy of vaccines for AIV.[15][16][17][18][19] As real-world outcomes of vaccine trials for rare diseases are challenging to evaluate, studies generally assess the development of antibodies in humans or human cells after vaccine testing. 

In patients requiring hospitalization for avian influenza, reported mortality is higher than 50% for all strains of AIV infection combined, although more detailed data suggests H7N9 infection is less deadly with 35% mortality than H5N1 with a 60% mortality rate.[20][2] As noted previously, likely, not all patients affected by the virus present to a hospital, and there may be many more with milder symptoms and reduced mortality. Regardless, all current information suggests that the virus is dangerous when infecting humans, and prognosis in hospitalized patients is generally poor.

Complications from AIV infection result from either organ failure or damage, iatrogenic injury during treatment, or coinfection.[9] Because severe disease is common, as is widespread organ failure, long term complications should be anticipated. Long term respiratory compromise is common in patients requiring extensive mechanical ventilation, and chronic kidney disease is possible in patients with acute kidney injury from AIV. As with other viral illnesses, bacterial coinfection is possible and should merit consideration any time a patient’s condition changes during the disease course or if it worsens after an episode of improvement.

Any patient hospitalized with a suspected or confirmed diagnosis of Avian Influenza should have an infectious disease consultation to better direct care and minimize complications. While the recommendations presented here are necessary for any patient with suspected avian influenza, an infectious disease consultant may be able to better direct treatment for specific avian influenza strains and manage treatment and patient expectations more appropriately. Additionally, in the United States, it is mandatory to report confirmed cases of avian influenza to the Centers for Disease Control (CDC).

Whenever there is a possible outbreak of avian influenza, the essential way to reduce the severity and population impact is to reduce the spread of the virus. Since the human-to-human transmission is uncommon, the focus should be on reinforcing appropriate sanitation habits in the population, especially those that work around birds or that are involved in food preparation.

Because disease outbreaks are rare and difficult to predict, well-controlled studies of treatment are nearly impossible. As such, most recommendations come from an expert consensus of review of previous outbreaks. The best way to reduce morbidity and mortality associated with avian influenza is to improve public knowledge of the disease, reduce the spread of infection once an outbreak is identified and educate vulnerable populations on risk reduction and early recognition of disease. While physicians can play an essential role in this, public health officials (often through media assistance) are critical to limiting the human impact of the disease. [Level 4]

When an outbreak is identified, it is crucial for public health officials to identify at-risk populations and to inform the public of risk factors and ways to detect infection. Because the presence of deadly disease in a community can incite fear and panic, announcements should include which populations are at low risk for contracting avian influenza. Those people who work with live or dead birds, including those who may handle poultry at restaurants, should be aware of symptoms of bird flu in themselves and co-workers and should be given directions for contacting local health officials and information for how to undergo evaluation if suspicion of infection is high. [Level 4]

Additionally, a high index of suspicion is often needed to diagnose early cases of avian influenza in a population. Care and detailed history-taking, as well as early testing in at-risk patients presenting with a severe viral infection, is needed to allow health care professionals to intervene early to restrict the impact of an outbreak. [Level 4]

There is currently an FDA-licensed vaccine for the H5N1 strain of avian influenza in the United States. In the case of an H5N1 outbreak in the United States, the CDC and public health officials may decide to vaccinate at-risk populations to reduce spread. Apart from the available H5N1 vaccine, no human vaccines exist for avian influenza, although there are currently vaccine development studies in progress that may result in more availability in the future (see above). [Level 4]

An interprofessional team is beneficial in the management of this disease. The emergency department and primary care providers should be cognizant of this diagnosis. Patients should receive a referral to infectious disease, intensivists, and pulmonologists. Critical care nurses monitor patients, answer patient questions, and provide updates to the team. Pharmacists review antiviral and other medications as to the dose and possible drug interactions and make recommendations to the clinicians where appropriate. With interprofessional collaboration and communication across both disciplines and even with media and other public health personnel, the risks of avian influenza can remain contained. [Level 5]